We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA, Industry to Nail Down Time for Biosimilar Fee Collection
FDA, Industry to Nail Down Time for Biosimilar Fee Collection
July 29, 2011
The FDA is developing several proposals for when to collect product development fees from biosimilar makers under the user fee program being negotiated with drug companies.